from big pharma to pre-ipo start up

CEO Christina Östberg Lloyd will be one of the speakers in the “Follow the money” session at SwedenBIO Summit on December 9. In an interview by SwedenBIO, Christina talks about her first few weeks as CEO of Pharmiva after eleven years as Medical and Clinical Director at Novo Nordisk.

– For the first three to four weeks, there has been full focus on preparing and conducting an investment round, a pre-IPO. There is a great interest. Getting to know the company’s employees and their skills, taking in all knowledge of the conditions and regulations for a company of this type and understanding how to manage a successful IPO, takes all my time now. In short, to learn to operate on a new playing field.

On December 9, you are one of the speakers in the session “Follow the money” at SwedenBIO Summit. What do you hope to have accomplished by then?

– Then we have worked through a clear and sustainable strategy. The pre-IPO will be closed, and we are in full swing with the preparations for our upcoming IPO. By then, we will also have kicked off a planned study and worked on optimizing the production. In parallel, the work of mapping relevant communication channels and building on our network continues.


To read the full article (in Swedish) click here

CEO Christina Österberg Lloyd


SwedenBIO is the national non-profit association for the life science industry in Sweden, with almost 300 members. Sweden has an innovative life science industry, strong academia and world leading infrastructure for research. SwedenBIO represent the leading life science companies in Sweden. Their members are companies active within pharma, biotech, diagnostics and medtech and comprise the entire range from small start-ups, to SMEs and large enterprises. Many are engaged in research and development. Other members are experts in fields such as IP, law, finance, product development, life science communication and business development.

Dare to talk about vaginal health

CEO and gynaecologist Christina Östberg Llloyd wants to encourage women to break existing tabus and speak up about the importance of vaginal health.

Bacterial vaginosis is the most common vaginal infection causes foul-smelling discharges. Untreated BV can cause stigmatisation and suffering among women, but few women contact healthcare – because they feel embarrassed.

Click on the link below to read or watch the whole interview (in Swedish).

Dare to talk about vaginal health


Christina Östberg Lloyd, CEO

Pharmiva will cure bacterial vaginosis – without antibiotics

Insikt Medicin interviews our CEO Christina Östberg Lloyd about her new assignment, the benefits of the technology platform Venerol® and the possibilities in future, effectively treating bacterial vaginosis without the risk of antimicrobial resistance.

Please read the full article here


Microscopic diagnosis of bacterial vaginosis. Vaginal secretions contain epithelial cells, so-called clue cells covered with bacteria Gardnerella vaginalis, 3D illustration


Christina Östberg Lloyd joins Pharmiva as new CEO

We are very pleased to announce that Christina Östberg Lloyd has started her new assignment as Pharmiva’s new CEO. Christina is a MD, specialized within gynecology and obstetrics, and has a long experience from leading positions in international life sciences companies (Novo Nordisk Scandinavia and Ferring Pharmaceuticals). Also, she holds the position as chairman of Life Science and Health in Skåne (FIRS) and before that chairman of Governing board Swelife (strategic innovation area VINNOVA). Christina is strongly committed to women’s health and finding new medical solutions to common problems affecting women’s vaginal health.








Pharmiva receives ISO certification

Pharmiva received ISO certification on 29th October 2019, for the quality management system for medical devices that fulfils the requirements of SS-EN ISO 13485:2016 with respect to design, production, marketing, and sales of products for women´s health.